Recent progress in the treatment of vascular calcification

Kidney International

Volumn 78, Issue 12, 2010, Pages 1232-1239

  O'Neill, W Charles ^a   Lomashvili, Koba A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

bone; chronic kidney disease; vascular calcification; vascular disease

Indexed keywords

ALENDRONIC ACID; ATORVASTATIN; BISPHOSPHONIC ACID DERIVATIVE; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENIC PROTEIN 7; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; CINACALCET; ETIDRONIC ACID; LANTHANUM CARBONATE; MAGNESIUM CARBONATE; MENAQUINONE; OSTEOPONTIN; PAMIDRONIC ACID; PHOSPHATE; PHOSPHATE BINDING AGENT; PHYTOMENADIONE; PYROPHOSPHATE; SEVELAMER; THIOSULFATE; UNCLASSIFIED DRUG; VITAMIN K GROUP; WARFARIN;

ACIDOSIS; ARTERY CALCIFICATION; BLOOD VESSEL CALCIFICATION; BONE DISEASE; BONE METABOLISM; CALCIUM BLOOD LEVEL; CARBOXYLATION; CHRONIC KIDNEY DISEASE; CORONARY ARTERY; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG TARGETING; HUMAN; KIDNEY FAILURE; LOW DRUG DOSE; MINERAL METABOLISM; NEPHROLITHIASIS; NONHUMAN; PATHOPHYSIOLOGY; PATIENT SAFETY; PH; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; REVIEW; SECONDARY HYPERPARATHYROIDISM;

EID: 78649663706     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.334     Document Type: Review

References (122)

1. Amann K. Media calcification and intima calcification are distinct entities in chronic kidney disease. J Am Soc Nephrol 2008; 3: 1599-1605.
2. Jeziorska M, McCollum C, Woolley DE. Calcification in atherosclerotic plaque of human carotid arteries: associations with mast cells and macrophages. J Pathol 1998; 185: 10-17.
3. Reddy J, Son H, Smith SJ et al. Prevalence of breast arterial calcifications in an ethnically diverse population of women. Ann Epidemiol 2005; 15: 344-350.
4. Iribarren C, Go AS, Tolstykh I et al. Breast vascular calcification and risk of coronary heart disease, stroke, and heart failure. J Womens Health 2004; 13: 381-389.
5. Moore S. Blood vessels and lymphatics. In: Damjanov I, Linder J (eds). Anderson's Pathology, 10th edn. Mosby: St Louis, 1996, p 1401.
6. Lachman AS, Spray TL, Kerwin DM et al. Medial Calcinosis of Monckeberg. A review of the problem and a description of a patient with involvement of peripheral, visceral and coronary arteries. Am J Med 1977; 63: 615-622.
7. Chowdhury UK, Airan B, Mishra PK et al. Histopathology and morphometry of radial artery conduits: basic study and clinical application. Ann Thorac Surg 2004; 78: 1614-1621.
8. Nielsen BB, Holm NV. Calcification in breast arteries. The frequency and severity of arterial calcification in female breast tissue without malignant changes. Acta Pathol Microbiol Immunol Scand A 1985; 93: 13-16.
9. Nakamura S, Ishibashi-Ueda H, Niizuma S et al. Coronary calcification in patients with chronic kidney disease and coronary artery disease. Clin J Am Soc Nephrol 2009; 4: 1892-1900.
10. Duhn V, Johnson SA, D'Orsi CJ et al. Detection of medial vascular calcification in ESRD by mammography. J Am Soc Nephrol 2008; 19: 112A (abstract).
11. Schwarz U, Buzello M, Ritz E et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 2000; 15: 218-223.
12. Raggi P, Boulay A, Chasan-Taber S et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002; 39: 695-701.
13. Campean V, Neureiter D, Nonnast-Daniel B et al. CD40-CD154 expression in calcified and non-calcified coronary lesions of patients with chronic renal failure. Atherosclerosis 2007; 190: 156-166.
14. Blacher J, Guerin AP, Pannier B et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38: 938-942.
15. Rutsch F, Vaingankar S, Johnson K et al. PC-1 nucleotide triphosphate pyrophosphohydrolase deficiency in idiopathic infantile arterial calcification. Am J Pathol 2001; 158: 543-554.
16. London GM, Guerin AP, Marchais SJ et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740.
17. Sigrist MK, Taal MW, Bungay P et al. Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in CKD 4 and 5 patients. Clin J Am Soc Nephrol 2007; 2: 1241-1248.
18. Block GA, Raggi P, Bellasi A et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71: 438-441.
19. Suki W, Zabaneh R, Cangiano JL et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007; 72: 1130-1137.
20. Fellstrom BC, Jardine AG, Schmieder RE et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. New Eng J Med 2009; 360: 1395-1407.
21. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. New Eng J Med 2005; 353: 238-248. (Pubitemid 41058323)
22. Verberckmoes SC, Persy V, Behets GJ et al. Uremia-related vascular calcification more than apatite deposition. Kidney Int 2007; 71: 298-303.
23. Henley C, Davis J, Miller G et al. The calcimimetic AMG 641 abrogates parathyroid hyperplasia, bone and vascular calcification abnormalities in uremic rats. Eur J Pharmacol 2009; 616: 306-313.
24. Schurgers LJ, Spronk HMH, Soute BAM et al. Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K in rats. Blood 2007; 109: 2823-2831.
25. Verberckmoes R, Bouillon R, Krempien B. Disappearance of vascular calcifications during treatment of renal osteodystrophy. Two patients treated with high doses of vitamin D and aluminum hydroxide. Annal of Intern Med 1975; 82: 529-533.
26. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. New Eng J Med 2000; 342: 1478-1483.
27. Jono S, Nishizawa Y, Morii H. Parathyroid hormone-related peptide as a local regulator of vascular calcification. Arterioscler Thromb Vasc Biol 1997; 17: 1135-1142.
28. Lomashvili K, Garg P, O'Neill WC. Chemical and hormonal determinants of vascular calcification in vitro. Kidney Int 2006; 69: 1464-1470.
29. Neves KR, Graciolli FG, Dos Reis LM et al. Vascular calcification: contribution of parathyroid hormone in renal failure. Kidney Int 2007; 71: 1262-1270.
30. Rosenheim AH, Robinson R. The calcification in vitro of kidney, lung and aorta. Biochem J 1934; 28: 712-719.
31. Lomashvili KA, Cobbs S, Hennigar RA et al. Phosphate-induced vascular calcification: role of pyrophosphate and osteopontin. J Am Soc Nephrol 2004; 15: 1392-1401.
32. Eilberg R, Mori K. Early stages of in vitro calcification of human aortic tissue. Nature 1969; 223: 518-520.
33. Lomashvili KA, Monier-Faugere M-C, Wang X et al. Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. Kidney Int 2009; 75: 617-625.
34. El-Abbadi MM, Pai AS, Leaf EM et al. Phosphate feeding induces arterial medial calcification in uremic mice: role of serum phosphorus, fibroblast growth factor-23, and osteopontin. Kidney Int 2009; 24: 1297-1307.
35. Adeney KL, Siscovick DS, Ix JH et al. Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol 2009; 20: 381-387.
36. Chertow GM, Raggi P, Chasan-Taber S et al. Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 1489-1496.
37. London GM, Marty C, Marchais SJ et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004; 15: 1943-1951.
38. Barreto DV, Barreto FC, Carvalho AB et al. Coronary calcification in hemodialysis patients: the contribution of traditional and uremia-related risk factors. Kidney Int 2006; 67: 1576-1582.
39. Mehrotra R, Budoff M, Christenson P et al. Determinants of coronary artery calcification in diabetics with and without nephropathy. Kidney Int 2004; 66: 2022-2031.
40. Yang H, Curinga G, Giachelli CM. Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. Kidney Int 2004; 66: 2293-2299.
41. Urry DW. Neutral sites for calcium ion binding to elastin and collagen: a charge neutralization theory for calcification and its relationship to atherosclerosis. Proc Natl Acad Sci USA 1971; 68: 810-814.
42. Reynolds JL, Joannides AJ, Skepper JN et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004; 15: 2857-2867.
43. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252.
44. Block GA, Spiegel DM, Ehrlich J et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68: 1815-1824.
45. Russo D, Miranda I, Ruocco C et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 2007; 72: 1255-1261.
46. Barreto DV, Barreto FC, de Carvalho AB et al. Phosphate binder impact on bone remodeling and coronary calcification- results from the BRiC study. Nephron Clin Pract 2008; 110: c273-c283.
47. Qunibi WY, Moustafa M, Muenz LR et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 2008; 51: 952-965.
48. Kalil RS, Flanigan MG, Stanford W et al. The effect of lanthanum carbonate (Fosrenol) on coronary artery calcification and endothelial function in hemodialysis patients. A pilot, prospective study. J Am Soc Nephrol 2009; 20: 399A (abstract).
49. Spiegel DM, Farmer B, Smits G et al. Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study. J Renal Nutrition 2007; 17: 416-422.
50. Rufenacht HS, Fleisch H. Measurement of inhibitors of calcium phosphate precipitation in plasma ultrafiltrate. Am J Physiol 1998; 246: F648-F655.
51. Mizobuchi M, Finch JL, Martin DR et al. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int 2007; 72: 709-715.
52. Wu-Wong JR, Noonan W, Ma J et al. Role of phosphorus and vitamin D analogs in the pathogenesis of vascular calcification. J Pharm Exp Therap 2006; 318: 90-98.
53. Henley C, Colloton M, Cattley RC et al. 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrol Dial Transplant 2005; 20: 1370-1377.
54. O'Neill WC, Wang X, Faugere M-C et al. Effect of calcitriol on vascular calcification and uremic osteodystrophy. J Am Soc Nephrol 2009; 20: 37A (abstract).
55. Jono S, Nishizawa Y, Shioi A et al. 1,25-dihydrozyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. Circulation 1998; 98: 1302-1306.
56. Mathew S, Lund RJ, Chaudhary LR et al. Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol 2008; 19: 1509-1519.
57. Zhang Y, Mathew S, Fang Y et al. The mechanism of vitamin D receptor activator (VDRA) inhibition of chronic kidney disease (CKD) stimulated vascular calcification (VC). J Am Soc Nephrol 2009; 20: 37A (abstract).
58. Russo D, Palmiero G, De Blasio AP et al. Coronary artery calcification in patients with CRF not undergoing dialysis. Am J Kidney Dis 2004; 44: 1024-1030.
59. Kawata T, Nagano N, Obi M et al. Cinacalcet suppresses calcification of the aorta and heart in uremic rats. Kidney Int 2008; 74: 1270-1277.
60. Raggi P, Chertow G, Block G et al. A randomized controlled trial to evaluate the effects of cinacalcet plus low dose vitamin D on vascular calcification in hemodialysis patients. Am J Kidney Dis 2010; 55: B92 (abstract).
61. Bleyer AJ, Burkart J, Piazza M et al. Changes in cardiovascular calcification after parathyroidectomy in patients with ESRD. Amer J Kid Dis 2005; 46: 464-469.
62. Sharma J, Khan A, Bailey J et al. Successful near-total parathyroidectomy inhibits long-term coronary calcification progression in patients undergoing hemodialysis. J Am Soc Nephrol 2008; 19: 724A (abstract).
63. O'Neill WC. Vascular calcification: not so crystal clear. Kidney Int 2007; 71: 282-283.
64. Russell RGG, Bisaz S, Fleisch H. Pyrophosphate and diphosphates in calcium metabolism and their possible role in renal failure. Arch Intern Med 1969; 124: 571-575.
65. Meyer JL. Can biological calcification occur in the presence of pyrophosphate? Arch Biochem Biophys 1984; 231: 1-8.
66. Francis MD, Russell RGG, Fleisch H. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathologic calcification in vivo. Science 1969; 165: 1264-1266.
67. Goding JW. Ecto-enzymes: physiology meets pathology. J Leukoc Biol 2000; 67: 285-308.
68. 0-nucleotide phosphodiesterase). Euro J Biochem 1993; 217: 421-428.
69. Goding JW, Terkeltaub RA, Maurice M et al. Ecto-phosphodiesterase/ pyrophosphatase of lymphocytes and non-lymphoid cells: structure and function of the PC-1 family. Immunol Rev 1998; 161: 11-26.
70. Murshed M, Harmey D, Millan JL et al. Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes Dev 2005; 19: 1093-1104.
71. Lomashvili KA, Khawandi W, O'Neill WC. Reduced plasma pyrophosphate levels in hemodialysis patients. J Am Soc Nephrol 2005; 16: 2495-2500.
72. O'Neill WC, Sigrist MK, McIntyre CW. Plasma pyrophosphate and vascular calcification in chronic kidney disease. Nephrol Dial Transplant 2009; 25: 187-191.
73. 3 in rats. Clin Sci 1968; 35: 363-372.
74. Tamura K, Suzuki Y, Matsushita M et al. Prevention of aortic calcification by etidronate in the renal failure rat model. Eur J Pharmacol 2007; 558: 159-166.
75. Price PA, Faus SA, Williamson MK. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 2001; 21: 817-824.
76. Hill JA, Goldin JG, Gjertson D et al. Progression of coronary artery calcification in patients taking alendronate for osteoporosis. Acad Radiol 2002; 9: 1148-1152.
77. Tanko LB, Qin G, Alexandersen P et al. Effective doses of ibandronate do not influence the 3-year progression of aortic calcification in elderly osteoporotic women. Osteoporos Int 2005; 16: 184-190.
78. Nitta K, Akiba T, Suzuki K et al. Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. Am J Kidney Dis 2004; 44: 680-688.
79. Hashiba H, Aizawa S, Tamura K et al. Inhibition of the progression of aortic calcification by etidronate treatment in hemodialysis patients: long-term effects. Therapeut Apheresis Dial 2006; 10: 59-64.
80. Ariyoshi T, Eishi K, Sakamoto I et al. Effect of etidronic acid on arterial calcification in dialysis patients. Clin Drug Invest 2006; 26: 215-222.
81. Hashiba H, Aizawa S, Tamura K et al. Inhibitory effects of etidronate on the progression of vascular calcification in hemodialysis patients. Therapeut Apheresis Dial 2004; 8: 241-247.
82. Toussaint ND, Lau KK, Strauss BJ et al. The effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. Am J Kidney Dis 2010; 56: 57-68.
83. Shiraishi N, Kitamura K, Miyoshi T et al. Successful treatment of a patient with severe calcific uremic arteriolopathy (calciphylaxis) by etidronate sodium. Am J Kidney Dis 2006; 48: 151-154.
84. Monney P, Nguyen QV, Perroud H et al. Rapid improvement of calciphylaxis after intravenous pamidronate therapy in a patient with chronic renal failure. Nephrol Dial Transplant 2004; 19: 2130-2132.
85. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998; 19: 80-100.
86. Toussaint ND, Elder GJ, Kerr PG. Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue. Clin J Am Soc Nephrol 2009; 4: 221-233.
87. O'Neill WC, Riser BL, Faugere M-C et al. Treatment of uremic vascular calcification with pyrophosphate. J Am Soc Nephrol 2009; 20: 36A (abstract).
88. Yatzidis H. Successful sodium thiosulfate treatment for recurrent calcium urolithiasis. Clin Nephrol 1985; 23: 63-67.
89. Yatzidis H, Agroyannis B. Sodium thiosulfate treatment of soft tissue calcifications in patients with end-stage renal disease. Perit Dial Bull 1987; 7: 250-252.
90. Cicone JS, Petronis JB, Embert CD et al. Successful treatment of calciphylaxis with intravenous sodium thiosulfate. Am J Kidney Dis 2004; 43: 1104-1108.
91. Brucculeri M, Cheigh J, Bauer G et al. Long-term intravenous sodium thiosulfate in the treatment of a patient with calciphylaxis. Sem Dialysis 2005; 18: 431-434.
92. Pasch A, Schaffner T, Huynh-Do U et al. Sodium thiosulfate prevents vascular calcifications in uremic rats. Kidney Int 2008; 74: 1444-1453.
93. Bodell MA, Deng J, Spector DA. Sodium thiosulfate (STS) prevents vascular calcification (VC) in rats with adenine-induced kidney disease. J Am Soc Nephrol 2008; 19: 520A (abstract).
94. Disthabanchong S, Adirekkiat S, Sumethkul V et al. Sodium thiosulfate delays the progression of coronary artery calcification in hemodialysis patients. J Am Soc Nephrol 2009; 20: 36A (abstract).
95. Asplin JR, Donahue SE, Lindeman C et al. Thiosulfate reduces calcium phosphate nephrolithiasis. J Am Soc Nephrol 2009; 20: 1246-1253.
96. Gimblett FGR, Monk CB. Spectrophotometric studies of electrolytic dissociation. I. Some thiosulfates in water. Trans Faraday Soc 1955; 51: 793-802.
97. Luo G, Ducy P, McKee MD et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix Gla protein. Nature 1997; 386: 78-81.
98. Meier M, Weng LP, Alexandrakis E et al. Tracheobronchial stenosis in Keutel syndrome. Eur Respir J 2001; 17: 566-569.
99. Price PA, Chan WS, Jolson DM et al. The elastic lamellae of devitalized arteries calcify when incubated in serum. Evidence for a serum calcification factor. Arterioscler Thromb Vasc Biol 2006; 26: 1079-1085.
100. Price PA, Faus SA, Williamson MK. Warfarin causes rapid calcification of the elastic lamella in rat arteries and heart valves. Arterioscler Thromb Vasc Biol 1998; 18: 1400-1407.
101. Koos R, Krueger T, Westenfeld R et al. Relation of circulating matrix Gla-Protein and anticoagulation status in patients with aortic valve calcification. Thrombosis and Haemostasis 2009; 101: 706-713.
102. Holden RM, Sanfilippo AS, Hopman WM et al. Warfarin and aortic valvecalcificationin hemodialysis patients. J Nephrol 2007; 20: 417-422.
103. Lerner RG, Aronow WS, Sekhri A et al. Warfarin use and the risk of valvular calcification. J Thromb Haemostasis 2009; 7: 2023-2037.
104. Diaz A, Hirway P, Pekow P et al. Risk factors in calcific uremic arteriolopathy: a case control study in chronic dialysis patients. J Am Soc Nephrol 2006; 17: 174A (abstract).
105. Villines TC, O'Malley PG, Feuerstein IM et al. Does prolonged warfarin exposure potentiate coronary calcification in humans? Results of the Warfarin and Coronary Calcification Study. Calcif Tissue Int 2009; 85: 494-500.
106. Geleijnse JM, Vermeer C, Grobbee DE et al. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. J Nutr 2004; 134: 3100-3105.
107. 1 intake and Coronary calcification. Coronary Artery Dis 2005; 16: 199-203.
108. Holden RM, Morton AR, Garland JS et al. Vitamins K and D status in stages 3-5 chronic kidney disease. Clin J Am Soc Nephrol 2010; 5: 590-597.
109. Pilkey RM, Morton AR, Boffa MB et al. Subclinical vitamin K deficiency in hemodialysis patients. Am J Kidney Dis 2007; 49: 432-439.
110. Holden RM, Iliescu E, Morton AR et al. Vitamin K status of Canadian peritoneal dialysis patients. Perit Dial Int 2008; 28: 415-418.
111. Malyszko J, Wolczynski S, Skrzydlewska E et al. Vitamin K status in relation to bone metabolism in patients with renal failure. Am J Nephrol 2002; 22: 505-508.
112. Vychytil A, Druml W. Vitamin K supplementation in patients on continuous ambulatory peritoneal dialysis. Lancet 1998; 351: 1734-1735.
113. Mendoza FJ, Lopez I, Montes de Oca A et al. Metabolic acidosis inhibits soft tissue calcification in uremic rats. Kidney Int 2008; 73: 407-414.
114. Davies MR, Lund RJ, Hruska KA. BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. J Am Soc Nephrol 2003; 14: 1559-1567.
115. Hruska KA, Mathew S, Saab G. Bone morphogenetic proteins in vascular calcification. Circ Res 2005; 97: 105-114.
116. Westenfeld R, Schafer C, Smeets R et al. Fetuin-A (AHSG) prevents extraosseous calcification induced by uraemia and phosphate challenge in mice. Nephrol Dial Transplant 2007; 22: 1537-1546.
117. Hunter GK, Hauschka PV, Poole AR et al. Nucleation and inhibition of hydroxyapatite formation by mineralized tissue proteins. Biochem J 1996; 317: 59-64.
118. Wada T, McKee MD, Steitz S et al. Calcification of vascular smooth muscle cell cultures. Inhibition by osteopontin. Circ Res 1999; 84: 166-178.
119. Steitz SA, Speer MY, McKee MD et al. Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. Am J Pathol 2002; 161: 2035-2046.
120. Ohri R, Tung E, Rajachar R et al. Mitigation of ectopic calcification in osteopontin-deficient mice by exogenous osteopontin. Calcif Tissue Int 2005; 76: 307-315.
121. Wang KX, Denhardt DT. Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev 2008; 19: 333-345.
122. El-Tanani MK. Role ofosteopontinin cellular signaling and metastatic phenotype. Frontiers Bioscience 2008; 13: 4276-4284.